International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and doce

20 May

Cervical Cancer

New Reference: Cemiplimab for Cervical Cancer

Open-label, multicenter, phase 3 trial (EMPOWER-Cervical 1) Recurrent or metastatic cervical carcinoma, progressed after prior platinum-containing therapy Cemiplimab (n=304) or sin

16 Mar

Non-Small Cell Lung Cancer

New Indication: Trastuzumab Deruxtecan for her2-Mutant NSCLC

Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight

20 May

GastroEsophageal Cancer

New Indication: Nivolumab in Esophageal SCC

Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy f

26 Nov

Hodgkin Lymphoma

New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma

Multicenter, randomized, open-label trial Stage 3 or 4 advanced Hodgkin’s lymphoma A+AVD (n:664) or ABVD (n:670)

20 May

Soft Tissue Sarcoma

New Indication: Selinexor for Advanced Dedifferentiated Liposarcoma

Phase II-III, multicenter, randomized, double-blind, placebo-controlled study (SEAL) Advanced dedifferentiated liposarcoma who received 2-5 lines chemotherapy Selinexor (N: 188) or

23 Sep

Diffuse Large B Cell Lymphoma

New Drug: Glofitamab for Large B Cell Lymphoma

Phase 2 study Relapsed or refractory DLBCL, transformed follicular lymphoma, high-grade B-cell lymphoma, or primary mediastinal large B-cell lymphoma Obinituzumab and Glofitamab (n

23 Sep

Multiple Myeloma

New Drug: Talquetamab for Multiple Myeloma

Multicenter, open-label, single-arm trial Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibit

23 Sep

Chronic Lymphocytic Leukemia

New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

Phase II, open label, multicenter (CLL-2-Give) Previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation GIVe (Venetoclax +

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries